Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies
<b>Rationale:</b> In the era of precision medicine, there is a growing need for rapid reliable <i>ex vivo</i> functional assays capable of predicting treatment efficacy. One drug class that may particularly benefit from such assays is BH3 mimetics. These small molecules antagonize anti-apoptotic proteins such as BCL-2, MCL-1, or BCL-XL, on which cancer cells depend for their survival. A functional assay known as BH3 profiling was previously developed to measure those dependencies through the use of specific BH3-only peptides. A variation of this technique, dynamic BH3 profiling (DBP), allows for measuring changes in those dependencies, after <i>ex vivo</i> treatment with a drug of interest. Though well-validated to predict clinical response in hematologic malignancies, BH3 profiling technique requires the use of specialized BH3-only peptides and requires significant optimization to achieve reproducible results. <b>Methods:</b> We used a toolkit of BH3 mimetics drugs as probes instead of BH3-only peptides. This technique reduces the complexity and cost by using Annexin V/7AAD staining instead of cytochrome c release as a functional readout for apoptosis. We also used cell lines as internal controls for a representative response to BH3 mimetics that allow us to easily compare and stratify patients according to their profile. <b>Results:</b> We demonstrate that our new protocol enables apoptotic dependencies to be measured efficiently across different hematologic malignancies. In addition to a detailed description of the assay, we describe the results in several models including cell lines and primary tumor cells, both at baseline and dynamically after <i>ex vivo</i> drug treatments. We also compared BH3 toolkit baseline results on cell lines with those obtained using conventional BH3 profiling. <b>Conclusion:</b> Overall, our data validates this streamlined BH3 drug toolkit, allowing for a more extensive use of the BH3 profiling technique.
Authors
- Jérôme Moreaux (ORCID: https://orcid.org/0000-0002-5717-3207)
- Charles Herbaux
- Sara Ovejero (ORCID: https://orcid.org/0000-0002-8354-856X)
- Hugues de Boussac
- Caroline Molinaro (ORCID: https://orcid.org/0000-0002-7002-5030)
- Valentin Jacquier
- Ouissem Karmous Gadacha
- Matthew Steven Davids (ORCID: https://orcid.org/0000-0003-4529-2003)
- Alexandre Romero (ORCID: https://orcid.org/0000-0001-6993-0351)
- Matthieu Abouladzé
- Ludovic Gabellier (ORCID: https://orcid.org/0000-0003-0663-8083)
- Ritu Somayaji
Institutions
- Centre National de la Recherche Scientifique (FR)
- Institut Universitaire de France (FR)
- Université de Montpellier (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Dana-Farber Cancer Institute (US)
- Institut de Génétique Humaine (FR)
Publication Details
- Journal
- Theranostics
- Published
- 2025-04-21
- DOI
- https://doi.org/10.7150/thno.107852
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94